Trials / Not Yet Recruiting
Not Yet RecruitingNCT07376720
A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Donghua Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
This research project includes patients with relapsed/refractory multiple myeloma (r/r MM) who have received more than three lines of treatment, including those with secondary recurrence, SCT recurrence, and refractory cases. Through this study, we aim to preliminarily determine the effectiveness of the treatment for r/r MM, with the expectation of providing new treatment methods to improve the survival rate of patients with r/r MM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells | Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells |
Timeline
- Start date
- 2026-02-15
- Primary completion
- 2028-10-30
- Completion
- 2029-10-30
- First posted
- 2026-01-29
- Last updated
- 2026-01-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07376720. Inclusion in this directory is not an endorsement.